用于戒烟的行为激活移动医疗应用:随机对照试点试验。

IF 3 2区 医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Jaimee L Heffner, Edit Serfozo, Kelsey Baker, Melissa Gasser, Noreen Watson, Stacey B Daughters, Elisardo Becoňa, Jennifer B McClure
{"title":"用于戒烟的行为激活移动医疗应用:随机对照试点试验。","authors":"Jaimee L Heffner, Edit Serfozo, Kelsey Baker, Melissa Gasser, Noreen Watson, Stacey B Daughters, Elisardo Becoňa, Jennifer B McClure","doi":"10.1093/ntr/ntae137","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Behavioral activation (BA) is an effective intervention for both depression and substance use disorders. Combining BA with a standard smoking cessation intervention may improve quit rates by addressing depressive symptoms, a key barrier to quitting. This study preliminarily evaluated the acceptability and efficacy of the BA-based Actify! mobile health application (mHealth app) for smoking cessation.</p><p><strong>Aims and methods: </strong>We conducted a pilot randomized controlled trial (n = 242) comparing Actify! with the National Cancer Institute's (NCI) app for smoking cessation (QuitGuide) on acceptability (user satisfaction, app openings), smoking abstinence, and mechanisms of change (BA and depressive symptoms) at 8 weeks and 6 months postrandomization. Participants were US adults recruited online who smoked daily.</p><p><strong>Results: </strong>Treatment satisfaction was uniformly higher in the Actify! arm. Number of app openings was similar across arms (M = 34.3 openings over 8 weeks in both arms). Self-reported 30-day point prevalence abstinence (PPA) at 8 weeks was 12.6% for Actify! versus 7.3% for QuitGuide. Differences in 30-day PPA continued through 6 months (18.5% for Actify! vs. 12.2% for QuitGuide). Changes between baseline and 8 weeks in depressive symptoms and BA favored Actify!. Planned subgroup analyses suggested greater benefit of Actify! among participants with pretreatment mild-to-moderate depression symptom severity compared to those with no depression symptoms.</p><p><strong>Conclusions: </strong>Actify! showed considerable promise as a novel mHealth treatment, as evidenced by its high usage and higher user satisfaction and quit rates than QuitGuide at both short- and long-term follow-up. The next step is to evaluate Actify! in a fully powered efficacy trial.</p><p><strong>Implications: </strong>Study findings demonstrate the promise of a BA-based mobile health app (Actify!) for smoking cessation as a population-level intervention that can effectively address depressive symptoms as a risk factor for worse smoking treatment outcomes. The Actify! app is the first standalone BA-based app to demonstrate potential for improved acceptability and efficacy relative to a standard care comparison app, with user satisfaction and smoking quit rates descriptively exceeding those of the NCI's QuitGuide app.</p>","PeriodicalId":19241,"journal":{"name":"Nicotine & Tobacco Research","volume":" ","pages":"18-27"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663802/pdf/","citationCount":"0","resultStr":"{\"title\":\"Behavioral Activation mHealth Application for Smoking Cessation: A Randomized Controlled Pilot Trial.\",\"authors\":\"Jaimee L Heffner, Edit Serfozo, Kelsey Baker, Melissa Gasser, Noreen Watson, Stacey B Daughters, Elisardo Becoňa, Jennifer B McClure\",\"doi\":\"10.1093/ntr/ntae137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Behavioral activation (BA) is an effective intervention for both depression and substance use disorders. Combining BA with a standard smoking cessation intervention may improve quit rates by addressing depressive symptoms, a key barrier to quitting. This study preliminarily evaluated the acceptability and efficacy of the BA-based Actify! mobile health application (mHealth app) for smoking cessation.</p><p><strong>Aims and methods: </strong>We conducted a pilot randomized controlled trial (n = 242) comparing Actify! with the National Cancer Institute's (NCI) app for smoking cessation (QuitGuide) on acceptability (user satisfaction, app openings), smoking abstinence, and mechanisms of change (BA and depressive symptoms) at 8 weeks and 6 months postrandomization. Participants were US adults recruited online who smoked daily.</p><p><strong>Results: </strong>Treatment satisfaction was uniformly higher in the Actify! arm. Number of app openings was similar across arms (M = 34.3 openings over 8 weeks in both arms). Self-reported 30-day point prevalence abstinence (PPA) at 8 weeks was 12.6% for Actify! versus 7.3% for QuitGuide. Differences in 30-day PPA continued through 6 months (18.5% for Actify! vs. 12.2% for QuitGuide). Changes between baseline and 8 weeks in depressive symptoms and BA favored Actify!. Planned subgroup analyses suggested greater benefit of Actify! among participants with pretreatment mild-to-moderate depression symptom severity compared to those with no depression symptoms.</p><p><strong>Conclusions: </strong>Actify! showed considerable promise as a novel mHealth treatment, as evidenced by its high usage and higher user satisfaction and quit rates than QuitGuide at both short- and long-term follow-up. The next step is to evaluate Actify! in a fully powered efficacy trial.</p><p><strong>Implications: </strong>Study findings demonstrate the promise of a BA-based mobile health app (Actify!) for smoking cessation as a population-level intervention that can effectively address depressive symptoms as a risk factor for worse smoking treatment outcomes. The Actify! app is the first standalone BA-based app to demonstrate potential for improved acceptability and efficacy relative to a standard care comparison app, with user satisfaction and smoking quit rates descriptively exceeding those of the NCI's QuitGuide app.</p>\",\"PeriodicalId\":19241,\"journal\":{\"name\":\"Nicotine & Tobacco Research\",\"volume\":\" \",\"pages\":\"18-27\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663802/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nicotine & Tobacco Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ntr/ntae137\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nicotine & Tobacco Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ntr/ntae137","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

背景:行为激活(BA)是治疗抑郁症和药物使用障碍的有效干预措施。将行为激活疗法与标准戒烟干预相结合,可通过解决抑郁症状这一戒烟的主要障碍来提高戒烟率。本研究初步评估了基于 BA 的 Actify!我们进行了一项试点随机对照试验(n=242),比较了 Actify!与美国国家癌症研究所(NCI)的戒烟应用程序(QuitGuide)在随机后 8 周和 6 个月的可接受性(用户满意度、应用程序打开率)、戒烟率和变化机制(行为激活和抑郁症状)。参与者是通过网络招募的每天吸烟的美国成年人:结果:Actify!治疗组的治疗满意度一致较高。两组的应用程序打开次数相似(两组在 8 周内的打开次数均为 34.3 次)。8周时,Actify!的30天自我报告戒烟率(PPA)为12.6%,而戒烟指南(QuitGuide)为7.3%。30 天 PPA 的差异持续到 6 个月(Actify!为 18.5%,QuitGuide 为 12.2%)。抑郁症状和行为激活在基线和 8 周之间的变化有利于 Actify!。计划进行的亚组分析表明,与没有抑郁症状的参与者相比,治疗前有轻度至中度抑郁症状的参与者从 Actify!Actify!作为一种新型的移动保健治疗方法,在短期和长期随访中的高使用率、用户满意度和戒烟率均高于《戒烟指南》,这充分证明了它的巨大前景。下一步是在一项完全有效的疗效试验中对 Actify!研究结果表明,基于行为激活(BA)的移动医疗戒烟应用程序(Actify!)作为一种人群干预措施,可以有效解决抑郁症状这一吸烟治疗效果较差的风险因素。Actify! 应用程序是首款基于行为激活的独立应用程序,与标准护理对比应用程序相比,它具有更高的可接受性和疗效,用户满意度和戒烟率均超过了美国国家癌症研究所的戒烟指南应用程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Behavioral Activation mHealth Application for Smoking Cessation: A Randomized Controlled Pilot Trial.

Introduction: Behavioral activation (BA) is an effective intervention for both depression and substance use disorders. Combining BA with a standard smoking cessation intervention may improve quit rates by addressing depressive symptoms, a key barrier to quitting. This study preliminarily evaluated the acceptability and efficacy of the BA-based Actify! mobile health application (mHealth app) for smoking cessation.

Aims and methods: We conducted a pilot randomized controlled trial (n = 242) comparing Actify! with the National Cancer Institute's (NCI) app for smoking cessation (QuitGuide) on acceptability (user satisfaction, app openings), smoking abstinence, and mechanisms of change (BA and depressive symptoms) at 8 weeks and 6 months postrandomization. Participants were US adults recruited online who smoked daily.

Results: Treatment satisfaction was uniformly higher in the Actify! arm. Number of app openings was similar across arms (M = 34.3 openings over 8 weeks in both arms). Self-reported 30-day point prevalence abstinence (PPA) at 8 weeks was 12.6% for Actify! versus 7.3% for QuitGuide. Differences in 30-day PPA continued through 6 months (18.5% for Actify! vs. 12.2% for QuitGuide). Changes between baseline and 8 weeks in depressive symptoms and BA favored Actify!. Planned subgroup analyses suggested greater benefit of Actify! among participants with pretreatment mild-to-moderate depression symptom severity compared to those with no depression symptoms.

Conclusions: Actify! showed considerable promise as a novel mHealth treatment, as evidenced by its high usage and higher user satisfaction and quit rates than QuitGuide at both short- and long-term follow-up. The next step is to evaluate Actify! in a fully powered efficacy trial.

Implications: Study findings demonstrate the promise of a BA-based mobile health app (Actify!) for smoking cessation as a population-level intervention that can effectively address depressive symptoms as a risk factor for worse smoking treatment outcomes. The Actify! app is the first standalone BA-based app to demonstrate potential for improved acceptability and efficacy relative to a standard care comparison app, with user satisfaction and smoking quit rates descriptively exceeding those of the NCI's QuitGuide app.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nicotine & Tobacco Research
Nicotine & Tobacco Research 医学-公共卫生、环境卫生与职业卫生
CiteScore
8.10
自引率
10.60%
发文量
268
审稿时长
3-8 weeks
期刊介绍: Nicotine & Tobacco Research is one of the world''s few peer-reviewed journals devoted exclusively to the study of nicotine and tobacco. It aims to provide a forum for empirical findings, critical reviews, and conceptual papers on the many aspects of nicotine and tobacco, including research from the biobehavioral, neurobiological, molecular biologic, epidemiological, prevention, and treatment arenas. Along with manuscripts from each of the areas mentioned above, the editors encourage submissions that are integrative in nature and that cross traditional disciplinary boundaries. The journal is sponsored by the Society for Research on Nicotine and Tobacco (SRNT). It publishes twelve times a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信